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Abstract
Purpose of review—Human immunodeficiency virus (HIV) is now managed as a chronic 
disease. Non-infectious pulmonary conditions have replaced infection as the biggest threat to lung 
health, particularly as HIV cohorts age, but there is no consensus on how best to maintain long-
term lung health. We review the epidemiology and pathogenesis of chronic obstructive pulmonary 
disease (COPD), pulmonary arterial hypertension (PAH) and lung cancer in HIV-seropositive 
individuals.
Recent Findings—Diagnoses of COPD are now up to 50% more prevalent in HIV-seropositive 
individuals than HIV-uninfected controls, and prospective pulmonary function studies find 
significant impairment in 7%–>50% of HIV-seropositive individuals. The prevalence of HIV-
PAH is 0.2%–0.5%, and lung cancer is 2–3 times more prevalent in HIV-seropositive individuals. 
Although host factors such as age and smoking have a role, HIV is an independent contributor to 
the pathogenesis of COPD, PAH and lung cancer. Chronic inflammation, immune senescence, 
oxidative stress and direct effects of viral proteins are all potential pathogenetic mechanisms. 
Despite their prevalence, non-infectious lung diseases remain under-recognized and evidence for 
effective screening strategies in HIV-seropositive individuals is limited.
Summary—COPD, PAH and lung cancer are a growing threat to lung health in the HAART era 
necessitating early recognition.
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Introduction
In countries with well-resourced health care systems, and increasingly in low and middle-
income countries (LMIC), human immunodeficiency virus (HIV) infection has become a 
chronic illness. The focus of care has shifted from management of AIDS-associated illnesses 
to maintaining long-term health through optimal disease control and the prevention of 
secondary, non-AIDS complications. Primary prevention of cardiovascular disease, for 
example, is now a routine activity in the HIV clinic. This practice followed epidemiological 
studies showing the increased risk of coronary artery disease with HIV and guidelines that 
supported primary prophylaxis (1, 2). Neurocognitive, bone and renal health are similarly 
monitored. By contrast, long-term respiratory health receives less attention in the clinic, yet 
there is significant increased risk of non-AIDS lung disease in HIV-seropositive individuals 
(3–8). This review focuses on the most prevalent of these, namely chronic obstructive 
pulmonary disease (COPD), pulmonary arterial hypertension (PAH) and lung cancer, 
discusses current thinking on how HIV contributes to their pathogenesis and sets out what 
evidence exists to guide the promotion of long-term lung health in the HIV clinic.
COPD in HIV
It had become apparent by the 1990s that HIV was associated with both impaired diffusion 
capacity and COPD (9). Both case-control and prospective longitudinal studies in largely 
therapy-naïve HIV-seropositive cohorts showed reduced forced expiratory volume (FEV1), 
impaired diffusing capacity for carbon monoxide (DLCO) and emphysema on computed 
tomography (CT) scan of the thorax, even when matched for smoking, sex and age (9–11). 
Self-reported COPD was almost 3 times more common in HIV-seropositive individuals 
(12). Either or both COPD and impaired DLCO were associated with lower CD4 counts, 
pulmonary and non-pulmonary AIDS-associated conditions and non-HIV factors; 
principally age, smoking and injecting drug use (IDU) (10, 13–15).
The association has persisted into the highly active antiretroviral therapy (HAART) era. A 
47% increased risk for COPD was seen in HIV-seropositive individuals of the prospective 
Veterans Aging Cohort (VACs), even after adjustment for known COPD risk factors (16). 
The same group have since reported data from the VACs and the 1999 Large Health Survey 
of Veteran Enrollees (LHS) and found the prevalence of COPD was 15% higher in HIV with 
a higher incidence rate ratio in individuals <50 years old (1.17 (95% confidence interval 
1.11–1.24) and younger non-smokers (1.25 (1.08–1.45)) compared with seronegative 
controls (5). Most recently, COPD has been identified as an increasing cause of death in the 
San Francisco HIV/AIDS registry (17). Incident COPD diagnoses have again been reported 
as higher in those with HIV in the Multicenter AIDS Cohort Study (MACS), although 
incident COPD was not higher in HIV-seropositive individuals in the Women’ s Interagency 
HIV Study (WIHS) cohort, possibly reflecting a diagnostic bias away from investigating 
chronic respiratory illness (18). This study also suggests that HIV clinicians might be under-
diagnosing obstructive lung disease given that those with HIV report more cough, dyspnea 
and wheeze than HIV-seronegative individuals, but are not more likely to have had 
pulmonary function testing (4, 18).
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These studies relied on diagnostic codes or self-report which may miss undiagnosed cases or 
incorrectly categorize lung disease. A more precise estimate of COPD prevalence and rates 
can be drawn from prospective clinic-based cohort-studies, typically involving 100–300 
individuals who undergo pulmonary function testing (PFT). These studies find Global 
Initiative for Chronic Obstructive Lung Disease (GOLD)-defined COPD (FEV1/FVC <70% 
or <lower limit of normal (LLN) and FEV1<80% predicted) in 7% to 23% of HIV-
seropositive individuals, 2 to 5-fold that of HIV-seronegative controls or reference 
populations, even in never-smokers (3, 4, 19–21). Impaired DLCO is even more prominent; 
30–64% of HIV-seropositive individuals record DLCO below predicted values (22–24). The 
prevalence of DLCO impairment is significantly greater than in HIV-seronegative controls 
and while higher in smokers, it is also raised in HIV-seropositive non-smokers (22, 23).
HIV in the pathogenesis of COPD
Several lines of evidence suggest that HIV is an independent contributor to COPD. Airflow 
obstruction and DLCO impairment continue to be associated with prior history of pulmonary 
infection (e.g. Pneumocystis pneumonia), smoking exposure, injecting drug use (IDU) and 
increasing age, as in the pre-HAART era (3, 19) (Figure 1). New work confirms that disease 
is more pronounced in older HIV-seropositive individuals (over 40 years) who smoke more, 
showing 17–25% prevalence of COPD, diffusion impairment in more than a third and CT-
confirmed emphysema in 26–37% (20, 21, 25, 26). Yet HIV, despite HAART, appears to 
remain as a driver; impairments in DLCO and airflow continue to progress over time in those 
receiving HAART (23, 27) and among IDU with established COPD, HIV is independently 
associated with increased acute exacerbations (28). Also new among the literature are 
studies from LMIC, where cohorts are typically younger with low rates of smoking 
providing further insight into the contribution of HIV, age and smoking to COPD. In 
Cameroon, COPD was 2.85 times more common in HIV-seropositive individuals and 90% 
were GOLD stage 2 or 3, yet the mean age was 42.6 and more than 80% were never-
smokers (29). COPD was, however, associated with moderate to heavy biomass exposure 
and prior pulmonary TB. This prevalence is similar to the 7.8% prevalence among a similar 
population of African participants of the Pulmonary Substudy of the Strategic Timing of 
AntiRetroviral Treatment (START) trial where 50% of COPD was in never-smokers (30).
The potential role of HIV as an independent factor in COPD development (figure 1) is also 
supported by associations between COPD and measures of HIV severity. Recent studies still 
find a correlation between lower CD4 and worse FEV1 (20, 21, 31), DLCO (22) or 
emphysema scores on CT (32), similar to associations reported in the pre-HAART era (13–
15). Meanwhile, undetectable viral load and the use of HAART are both protective factors 
(22, 27).
It is possible that the immune activation that persists with HAART is implicated in COPD 
pathogenesis. The observation by Diaz et al. that emphysema in HIV was associated with 
increased numbers of cytotoxic T cells in the lung (10) has been followed by new 
associations between PFT abnormalities and measures of immune activation including CD8 
T cell activation, CD4 T cell death receptor expression and levels of IL-6, sCD14, D-Dimer 
and IL-8 in the BAL, sputum or blood (31, 33–35). The importance of HIV-induced 
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inflammation in parenchymal damage is supported by a study in which smokers and never-
smokers were analyzed separately; impaired DLCO was found in the never-smokers and, in 
this group, it correlated with airway inflammation but not FEV1/FVC or CT measures of 
emphysema as seen in the smokers (26). The dysregulated immune phenotypes of HIV and 
COPD share some common CD8 T cell features (36, 37) and have both been described as 
having features of accelerated immune senescence (5, 38), a hypothesis reinforced by the 
recent findings that reduced leukocyte telomere length is associated with PFT abnormalities 
and CT emphysema scores in HAART-treated HIV-seropositive cohorts (35, 39).
It is well documented that HIV is associated with oxidative stress (reviewed in (40)) and 
oxidant/antioxidant imbalance in the lung is a likely mechanism of airway damage; HIV, 
and specifically gp120 and tat, cause oxidative stress and alveolar epithelial barrier 
dysfunction in the lungs of animal models (41, 42) while the antioxidant glutathione (GSH) 
is reduced in both the plasma (43, 44) and the lungs (45, 46) of HIV seropositive individuals 
and may not return to normal with ART (47). Meanwhile, there is a compensatory GSH 
response in more emphysematous upper lobes of HIV-seropositive smokers and non-
smokers (48). Oxidative stress also contributes to the pathogenesis of COPD; for instance 
GSH is reduced and linked to impaired nuclear factor (erythroid-derived 2)-like (NRF)-2 
responses (reviewed in (49)), which are also documented in HIV (40). Confirming the 
relevance of oxidative stress, antioxidant N-acetylcysteine has been demonstrated to reduce 
COPD exacerbations (50).
The HIV virus and its secreted proteins may also act directly to cause lung damage. gp120 
can induce mucus production from and cause damage to bronchial epithelial cells (51, 52), 
and greater levels of HIV RNA have been detected in more emphysematous regions of the 
lung (53). This finding is not solely relevant in the HAART naïve lung, as new evidence 
from HAART-treated macaques and virally-suppressed individuals indicates that the 
alveolar space may be a distinct compartment with persistent viral replication (54–57).
Finally, new data from the US Lung HIV Microbiome Program demonstrate that those with 
HIV and COPD have overrepresentation of fungal species (58), while there is an altered 
lung microbiome in HIV in general, in one series with increased T. whipplei, although the 
microbiome may be restored with HAART (59, 60). It is at least plausible that the lung 
microbiome could have a role, as it is well-established that bacterial microbiota in the lung 
are altered in COPD. The exact mechanism by which the microbiome contributes to disease 
progression is not yet known (61).
Pulmonary Arterial Hypertension in HIV
The prevalence of pulmonary arterial hypertension in HIV (HIV-PAH) is reported at 0.2% 
to 0.5% (6, 7, 62); however, prospective screening studies that use transthoracic echo to 
measure pulmonary artery pressure (PAP), rather than right heart catheterization (RHC), 
tend to report higher prevalence (63–66). PAH is defined as an elevated mean (m) PAP on 
RHC whereas echo estimates systolic (s) PAP as a surrogate for mPAP. sPAP is derived 
from measurements of the tricuspid valve regurgitant jet velocity, which may either under- 
or overestimate true mPAP (67). Furthermore, age- and weight-based reference values must 
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be used as sPAP increases with age and body mass index. For example, 6% of individuals 
aged over 50 have sPAP>40mmHG (68). Finally, left ventricular diastolic dysfunction, 
which can alter sPAP and is common in HIV, must be accounted for (69). Nevertheless, 
even on RHC studies, the prevalence is still some hundred-fold that of the normal population 
(70), and the VACs database study that relied on much less sensitive diagnostic coding of 
HIV-PAH still reported a significantly increased prevalence of 0.2% and incident rate ratio 
of 1.57(5).
These studies span the current and pre-HAART eras and, overall, show no clear change in 
HIV-PAH prevalence. In fact, two studies have found that HAART use correlates with HIV-
PAH prevalence (64, 66). However, HIV-PAH has also been associated with higher HIV 
viral load (VL) and lower CD4 cell counts (33, 65); and longitudinal follow-up of pressure 
gradients and 6-minute walk tests in HIV-PAH shows that progression can be slowed by 
HAART (71, 72). Additionally, both HAART and PAH-specific therapy are associated with 
better outcomes in HIV-PAH patients (73, 74).
Pathogenesis of HIV-PAH
PAH prevalence in HIV-seropositive individuals is likely to be increased, in part by the co-
occurrence of other PAH risk factors such as venous thromboembolic disease, IDU and 
hepatitis C virus (HCV) infection (75) (figure 2). HIV does appear to be an independent risk 
factor for PAH, and simian immunodeficiency virus (SIV)-infected macaque studies 
demonstrate a high frequency of PAH development (76). HIV-PAH shares the 
histopathological features of hypertrophy and proliferation of the arterial wall and plexiform 
lesions with idiopathic PAH, despite not directly infecting pulmonary endothelial cells (77), 
which has led to suggestions that the two have common pathogenic mechanisms, albeit with 
different triggers (78). Chief among these are the HIV proteins; Nef may contribute to 
pulmonary vascular remodeling in a primate model and is found in human endothelial cells 
(79, 80). Distinct nef polymorphisms are associated with HIV-PAH, although the causal 
relationship cannot be determined (81). HIV tat suppresses bone morphogenic protein 
receptor 2 (BMPR-2), implicated in idiopathic PAH. Tat can induce oxidative stress in 
pulmonary endothelial cells and has recently been found to act synergistically with cocaine 
to induce reactive oxygen species (ROS)-mediated endothelial damage (82–85). Finally, 
gp120 can cause apoptosis and oxidative stress in pulmonary endothelial cells (77, 86), with 
the latter also resulting in HIF-1ř-mediated upregulation of platelet derived growth factor, 
implicated in PAH (84). Further evidence of the importance of gp120, and perhaps a 
potential therapeutic approach, come from a new study that prevented gp120-induced 
pulmonary artery smooth muscle cell hypertrophy by blocking chemokine receptor 5 
(CCR5) engagement using Maraviroc (ViiV Healthcare, Middlesex, UK) in a mouse model 
of hypoxia-induced PAH (87). gp120 also increases secretion of another important PAH 
factor, endothelin-1 (88). Endothelin-1 levels are higher in HIV-seropositive individuals and 
correlate with HIV-PAH severity (89).
Reports of associations between markers of systemic and pulmonary inflammation with 
HIV-PAH severity, including interleukin (IL)-8, interferon (IFN)-ś and, most recently, IL-6 
and the endogenous inhibitor of endothelial nitric oxide synthase asymmetric 
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dimethylarginine (ADMA)(33, 90), support the hypothesis that HIV-PAH is also driven by 
inflammation, even during HAART (91).
Lung cancer in HIV
Lung cancer, a non-AIDS defining cancer (NADC), is 2–3 times more common (8) and 
carries a higher mortality in HIV-seropositive individuals than in the general population 
(92–94). This higher mortality may result from lung cancer presenting at a more advanced 
stage in HIV-seropositive individuals (95), rather than due to any difference in the subtypes, 
which are broadly similar to the general population (96). As the HAART era continues, the 
number of HIV-seropositive individuals with lung cancer is growing in proportion. In 
France, it is now the leading cause of death in HIV (97).
The pathogenesis of lung cancer in HIV
Smoking is more common in HIV-seropositive individuals and continues to be the major 
contributing factor to lung cancer in this population (98, 99). Recent data emphasize that 
smoking is central to the risk of non-virological cancers (100, 101). However, lower CD4 
and higher VL are also relevant to cancer mortality and the association with HIV is 
independent after adjustment for other factors (96, 99). Additionally, Sigel et al. have 
reported that CD4 counts < 500 cells/mm3 and reduced CD4/CD8 ratios were associated 
with increased lung cancer risk (102). While the pathogenic mechanism linking HIV to lung 
cancer is not understood, these latter studies implicate immunosuppression, similar to its 
role in the pathogenesis of other malignancies in HIV (103, 104). HIV-associated 
inflammation is also likely to be relevant, as markers of inflammation (IL-6, D-dimer and C-
reactive protein) have been linked to both infection-related and non-infection-related cancers 
in HIV (105) and more specifically to lung cancer (106). Finally, inflammation may also 
underlie the contribution of recurrent bacterial pneumonia to an increased risk of lung cancer 
in HIV (107).
Screening for Lung Disease in HIV
Given the disparity between COPD diagnoses and rates of respiratory symptoms or PFT 
abnormalities in prospective studies, the current approach is inadequate to identify COPD in 
the HIV clinic (4, 18). Whether this lack of detection is due to poor physician awareness is 
not clear, but one barrier may be that screening often requires referral and evaluation 
elsewhere (108). The use of readily-available screening tools like peak flow, with or without 
symptom questionnaires, may be an approach that identifies those who need spirometry 
(109), but there remains a lack of prospective trials to guide an evidence-based approach to 
COPD screening in the HIV clinic.
Screening for HIV-PAH is more difficult. Prevalence is lower than COPD and symptoms of 
fatigue, dyspnea and cough may initially be absent (64). Echo-based screening may both 
over and under-diagnose PAH depending on sPAP cut-offs used (110, 111). These 
observations lead some to conclude screening asymptomatic HIV-seropositive patients for 
PAH should not be performed (69). The invasiveness and availability of RHC limit its use as 
a screening tool; however, growth differentiation factor (GDF)-15 and N-terminal pro-B-
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type natriuretic peptide (NT-proBNP) in serum are strongly associated with increased sPAP 
(63, 111), so could have potential as biomarkers in a screening protocol.
Radiographically, the appearance of lung cancer in HIV is similar to that of HIV-
seronegative individuals (112) and given the success of lung cancer screening trials in high-
risk groups (113), the use of CT screening has been investigated in HIV. Due to the presence 
of other lung pathology in HIV-seropositive individuals, such as scarring from previous 
infection (25), there might be unacceptably high rates of false positive scans resulting in 
significant over-investigation. This concern is borne out by Hulbert et al. (114) who found 
pulmonary nodules in more than 20% of participants, but detected only a single lung cancer 
in 678 person-years’  screening of a high-smoking HIV cohort. They concluded that 
screening might not be worthwhile except in older age groups. In contrast, the Examinations 
of HIV Associated Lung Emphysema (EXHALE) study investigators found no difference in 
rates of abnormal CT screening scans compared with HIV-seronegative individuals, albeit 
only in those with a CD4 > 200 cells/mm3 (115). Initial reports from the French HIV 
CHEST study, targeting HIV-seropositive individuals over 40 years of age with significant 
recent smoking history, suggest that using low dose CT thorax for early lung cancer 
diagnosis and nodule follow-up may be feasible in HIV-seropositive smokers (116). 
Currently, lung cancer screening of HIV-seropositive populations with CT is not 
recommended beyond the guidelines for the general population (117).
Conclusions
Non-infectious pulmonary complications are more common in HIV-seropositive individuals, 
and their prevalence and severity will likely increase as the HIV-seropositive population 
ages. To maintain lung health in long-standing HIV, these complications have to be 
prevented, recognized and managed. Starting all individuals with HIV on HAART, as now 
advocated by guidelines (118), and promoting smoking cessation will undoubtedly aid 
prevention. However, the evidence base for effective strategies to identify COPD, PAH and 
lung cancer in HIV clinics is weak. Furthermore, the risk factors for each condition may be 
different, and there is much still to learn about the underlying mechanisms.
An individualized, patient-centered approach should be taken. HIV clinicians must be alert 
to the early symptoms of respiratory disease, particularly exertional breathlessness, and have 
a low threshold (and tenacious insistence) for organizing basic spirometry and DLCO 
measurement. Echocardiography and CT of the thorax are readily available and can detect 
emphysema, HIV-PAH and lung cancers, but may lack specificity for the latter two. In the 
absence of HIV-specific evidence, the screening for these conditions should follow 
guidelines for HIV-seronegative individuals.
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Key Points
• Chronic obstructive pulmonary disease (COPD), pulmonary arterial 
hypertension (PAH) and lung cancer are all more common in HIV-seropositive 
individuals than in the general population in the era of highly active 
antiretroviral therapy (HAART).
• Chronic HIV-associated lung diseases are driven by the virus itself, non-HIV 
risk factors that are more prevalent in HIV-seropositive individuals such as 
smoking and injecting drug use (IDU) and ageing of the HIV-seropositive 
population.
• Clinicians caring for HIV-seropositive patients should be alert to these 
conditions, but current evidence does not indicate that screening and diagnostic 
approaches should differ from the general population.
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Figure 1. 
The potential contribution of host factors and HIV to the development of COPD in HIV-
seropositive individuals
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Figure 2. 
The role of viral and other factors in HIV-PAH pathogenesis
IL – interleukin, IFN – interferon, HIF – hypoxia inducible factor, PDGF – platelet derived 
growth factor, BMPR - bone morphogenic protein receptor, HCV – hepatitis C virus
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